29 April 2022
Diurnal Group plc
("Diurnal" or the "Company")
Total Voting Rights
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that pursuant to its block admission facility, details of which were announced on 13 December 2021, it has recently issued 383,002 ordinary shares of £0.05 each in the Company ("Ordinary Shares") in satisfaction of the exercise of options. The new Ordinary Shares rank pari passu with the Company's existing shares.
In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, as of 29 April 2022, the Company has 169,719,533 Ordinary Shares in issue. There are no shares held in treasury. The total number of voting rights in the Company is therefore 169,719,533.
The above figure of 169,719,533 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
|
For further information, please visit www.diurnal.co.uk or contact: |
|
|
|
|
|
Diurnal Group plc |
+44 (0)20 3727 1000 |
|
Richard Bungay, Interim Chief Executive Officer |
|
|
|
|
|
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker) |
+44 (0)20 7886 2500 |
|
Corporate Finance: Freddy Crossley, Emma Earl |
|
|
Corporate Broking: Rupert Dearden |
|
|
|
|
|
Stifel Nicolaus Europe Limited (Joint Corporate Broker) |
+44 (0) 20 7710 7600 |
|
Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea, William Palmer-Brown |
|
|
Corporate Broking: Nick Adams, Nick Harland |
|
|
|
|
|
FTI Consulting (Media and Investor Relations) |
+44 (0)20 3727 1000 |
|
Simon Conway |
|
|
Victoria Foster Mitchell |
|
|
Alex Davis |
|
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
